FDA Approves Setmelanotide as Treatment for Acquired Hypothalamic Obesity
The U.S. Food and Drug Administration (FDA) has approved setmelanotide as a new treatment option for individuals suffering from acquired hypothalamic obesity, a rare condition characterized by rapid and uncontrollable weight gain. This approval follows the publication of results from the Phase 3 TRANSCEND clinical trial in The New England Journal of Medicine, marking a significant advancement in the management of this condition.
Acquired hypothalamic obesity typically arises after damage to the hypothalamus, the brain region that regulates hunger and energy expenditure. This condition is most commonly seen in children following treatment for certain brain tumors. Dr. Reema Habiby, Head of Endocrinology at Lurie Children’s Hospital and co-author of the study, highlighted the emotional toll this condition takes on families, noting that children often struggle with weight gain despite efforts to maintain a healthy lifestyle due to impaired hunger signals and low energy expenditure.
The TRANSCEND trial is noted as the largest and longest study of its kind for this condition, involving both pediatric and adult patients aged four years and older. Participants were randomly assigned to receive either setmelanotide or a placebo for a duration of one year. The results demonstrated robust improvements in weight management and hunger regulation among those treated with setmelanotide.
Dr. Habiby expressed optimism regarding the approval, stating, "For many families, this condition is heartbreaking. Until now, there has not been an approved treatment that addressed the underlying cause of the disease. These results offer real hope to children and families who have had very few options."
The study found that setmelanotide was generally well tolerated, with no new safety concerns identified during the trial period. Acquired hypothalamic obesity can lead to constant feelings of hunger, a slowed metabolism, and significant weight gain that is resistant to conventional diet and exercise methods. This condition can develop not only after brain tumor treatments but also following traumatic brain injuries, strokes, or severe inflammation.
Dr. Habiby noted that this approval is the result of years of collaboration among researchers, physicians, patients, and families worldwide. The treatment aims to address the biological underpinnings of the condition rather than merely managing its symptoms, offering a new avenue for those affected.
Lurie Children’s Hospital continues to spearhead research initiatives focused on innovative treatments for rare endocrine and metabolic disorders, striving to provide families with access to promising therapies through clinical trials and specialized care. The Phase 3 TRANSCEND trial was a global, randomized, double-blind, placebo-controlled study that evaluated the efficacy and safety of setmelanotide in patients aged four and older, with a total of 120 participants involved. The primary endpoint was the mean percent change in body mass index (BMI) after 52 weeks of treatment, with topline results being previously announced in April 2025.




